Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis

摘要

The present invention is a method of treating a patient who has developed non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS), wherein the rate of change of the revised amyotrophic lateral sclerosis functional assessment scale (ALSFRS-R) prior to initiation of treatment is <1.1 points/ In a method, wherein the method comprises administering a tyrosine kinase inhibitor or a mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient. it's about